GlassScriptPhysician profile
Pooja Poudel
NPI 1588186142
$2,547.76
in general payments reported to CMS, 2019-2025
21 companies · $892 in 2025
The $892 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $298 · 2024: $1,359 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.35 | 2023-2025 | |
| Amgen INC. | $456.06 | 2023-2025 | Enbrel, Evenity, Otezla |
| Aurinia Pharma U.S., INC. | $193.27 | 2024-2025 | Lupkynis |
| Janssen Biotech, INC. | $181.83 | 2023-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $163.46 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $156.17 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.43 | 2024-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.61 | 2024-2025 | Ofev, Cyltezo |
| Genzyme Corporation | $84.40 | 2025 | |
| Glaxosmithkline, LLC. | $72.09 | 2024-2025 | Benlysta |
| Radius Health, INC. | $50.45 | 2023-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $47.12 | 2024-2025 | Acthar |
| Sobi, INC | $46.94 | 2025 | |
| Ucb, INC. | $41.10 | 2023-2024 | Cimzia |
| Genentech USA, INC. | $35.96 | 2023-2025 | Actemra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $33.42 | 2024 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $24.14 | 2024 | Arcalyst |
| Ferring Pharmaceuticals INC. | $23.28 | 2025 | Euflexxa |
| Scilex Pharmaceuticals INC. | $17.69 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.24 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.75 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Poudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.